United Therapeutics (UTH) Stock Statistics & Valuation Metrics
Total Valuation
United Therapeutics has a market cap or net worth of EUR 22.92B. The enterprise value is EUR 22.15B.
- Market Cap
- EUR 22.92B
- Enterprise Value
- EUR 22.15B
Share Statistics
United Therapeutics has 42,890,694 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 42,890,694
- Owned by Insiders
- 1.95%
- Owned by Institutions
- 3.61%
Financial Efficiency
United Therapeutics’s return on equity (ROE) is 0.19 and return on invested capital (ROIC) is 16.13%.
- Return on Equity (ROE)
- 0.19
- Return on Assets (ROA)
- 0.17
- Return on Invested Capital (ROIC)
- 16.13%
- Return on Capital Employed (ROCE)
- 0.21
- Revenue Per Employee
- 2.27M
- Profits Per Employee
- 953.36K
- Employee Count
- 1,400
- Asset Turnover
- 0.40
- Inventory Turnover
- 2.10
Valuation Ratios
The current PE Ratio of United Therapeutics is 19.81. United Therapeutics’s PEG ratio is 2.18.
- PE Ratio
- 19.81
- PS Ratio
- 8.14
- PB Ratio
- 3.99
- Price to FCF
- 23.49
- Price to Operating Cash Flow
- 15.13
- PEG Ratio
- 2.18
Income Statement
In the last 12 months, United Therapeutics had revenue of 3.18B and earned 1.33B in profits. Earnings per share was 30.13.
- Revenue
- 3.18B
- Gross Profit
- 2.80B
- Operating Income
- 1.52B
- Pretax Income
- 1.71B
- Net Income
- 1.33B
- EBITDA
- 1.82B
- Earnings Per Share (EPS)
- 30.13
Cash Flow
In the last 12 months, operating cash flow was 1.69B and capital expenditures -592.20M, giving a free cash flow of 1.09B billion.
- Operating Cash Flow
- 1.69B
- Free Cash Flow
- 1.09B
- Free Cash Flow per Share
- 25.66
Dividends & Yields
United Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 4.26%
- Earnings Yield
- 5.14%
Stock Price Statistics
- Beta
- 0.26
- 52-Week Price Change
- 37.28%
- 50-Day Moving Average
- 457.53
- 200-Day Moving Average
- 458.62
- Relative Strength Index (RSI)
- 70.91
- Average Volume (3m)
- 44
Important Dates
United Therapeutics upcoming earnings date is Nov 04, 2026, Before Open (Not Confirmed).
- Last Earnings Date
- Aug 05, 2026
- Next Earnings Date
- Nov 04, 2026
- Ex-Dividend Date
- ―
Financial Position
United Therapeutics as a current ratio of 6.60, with Debt / Equity ratio of 0.53%
- Current Ratio
- 6.60
- Quick Ratio
- 6.28
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -0.84
- Interest Coverage Ratio
- 77.81
Taxes
In the past 12 months, United Therapeutics has paid 379.20M in taxes.
- Income Tax
- 379.20M
- Effective Tax Rate
- 0.22
Enterprise Valuation
United Therapeutics EV to EBITDA ratio is 14.24, with an EV/FCF ratio of 21.84.
- EV to Sales
- 7.57
- EV to EBITDA
- 14.24
- EV to Free Cash Flow
- 21.84
- EV to Operating Cash Flow
- 14.17
Balance Sheet
United Therapeutics has EUR 2.66B in cash and marketable securities with EUR 0.00 in debt, giving a net cash position of EUR 2.66B billion.
- Cash & Marketable Securities
- EUR 2.66B
- Total Debt
- EUR 0.00
- Net Cash
- EUR 2.66B
- Net Cash Per Share
- EUR 62.07
- Tangible Book Value Per Share
- EUR 147.56
Margins
Gross margin is 86.14%, with operating margin of 44.49%, and net profit margin of 41.56%.
- Gross Margin
- 86.14%
- Operating Margin
- 44.49%
- Pretax Margin
- 49.87%
- Net Profit Margin
- 41.56%
- EBITDA Margin
- 53.15%
- EBIT Margin
- 50.25%
Analyst Forecast
The average price target for United Therapeutics is EUR 597.51, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- EUR 597.51
- Price Target Upside
- 11.14% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 14
- Revenue Growth Forecast
- -4.46%
- EPS Growth Forecast
- 1.84%
Scores
- Smart Score
- 8
- AI Score
- ―